Document Type : Regular Article
Authors
1
Department of Biology, College of Science, University of Hafr Albatin, P. O. Box: 1803, Hafr Al Batin, Saudi Arabia
2
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hafr Al Batin, P. O. Box: 1803, Hafr Al Batin 31991, Saudi Arabia
3
College of Pharmacy, Middle East University, Amman, 11831, Jordan
4
Department of Pediatrics, College of Medicine, Najran University, Najran, Saudi Arabia
5
Department of Biochemistry, CMH Lahore Medical College & Institute of Dentistry, Lahore, Pakistan
6
College of Pharmacy, University of Hafr Al Batin, Kingdom of Saudi Arabia
7
School of Biological Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia
8
Professor of Biochemistry, Department of Pharmacy Practice, University of Hafr Al Batin, Saudi Arabia
10.22036/pcr.2022.351595.2147
Abstract
Selected monoclonal antibody molecules were conducted using the antibody–antigen docking mode, as well as the antibody-antigen docking approach.Objective of the study was to check effects of CetuximabCOVID-19 proteins (Nsp15 and 3CLpro) by using antibody–antigen docking mode, as well as the antibody-antigen docking approach.The results of molecular docking revealed that Cetuximab, a cancer-fighting antibody, ranks first among antibodies to both COVID-19 proteins (Nsp15 and 3CLpro).In cetuximab–3CLpro and cetuximab–Nsp15 complexes, the antigen interacts with both antibody chains, H and L.According to the findings, Cetuximab can be added to the COVID-19 treatment protocol, which may have the desired effect of inhibiting viral replication and decreasing mortality by targetingCOVID-19 proteins (Nsp15 and 3CLpro).Validation of these computational findings will require additional in vitro and in vivo research, which can be considered as a contribution in the field of biotechnology
Graphical Abstract
Keywords
)
)